Shanghai Ddsome Laboratories Co., Ltd announced that it has raised series A funding on July 7, 2023. The transaction included participation from new investor Zhejiang Huahai Pharmaceutical Co., Ltd., and returning investor Zhejiang Starry Pharmaceutical Co.,Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.64 CNY | -2.62% | +0.56% | -10.23% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
17.45 CNY | -4.33% | +4.18% | 3.54B | ||
12.64 CNY | -2.62% | +0.56% | 599M | ||
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.23% | 599M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 603520 Stock
- News Zhejiang Starry Pharmaceutical Co.,Ltd.
- Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd.